Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings